Recruiting PHASE2 INTERVENTIONAL 2-arm NCT07025174

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer (SAIB)

Evaluation of the Effect of Sequential Anti-angiogenic Therapy Following Immune Therapy Progression on Survival in Patients With Advanced Biliary Tract Malignancies: A Randomized, Multi-center, Exploratory Clinical Study

Sponsor: First Affiliated Hospital of Zhejiang University

Conditions Bile Duct Carcinoma Biliary Tract Cancer Cholangiocarcinoma Gall Bladder Cancer

Interventions Anlotinib Gemcitabine, Cisplatin Oxaliplatin + 5-Fluorouracil/Leucovorin PD-1/CTLA-4 Dual Functional Antibody

Updated 1 time since 2025 Last updated: Jun 10, 2025 Started: Jun 1, 2025 Primary completion: Dec 31, 2026 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07025174, this PHASE2 trial focuses on Bile Duct Carcinoma and Biliary Tract Cancer and remains actively recruiting participants. Sponsored by First Affiliated Hospital of Zhejiang University, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

1 version recorded

Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Zhejiang University

Data source: First Affiliated Hospital of Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China